Key clinical point: Lipophilic statin use may reduce mortality risk in patients with ovarian cancer.
Major finding: Lipophilic statin use was associated with a 43% reduction in mortality (weighted hazard ratio, 0.57).
Study details: An observational study of 10,062 patients with epithelial ovarian cancer, 2,621 of whom were exposed to statins.
Disclosures: The Department of Defense and the Breast Cancer Research Foundation funded the study. The researchers disclosed no conflicts of interest.
Visvanathan K et al. AACR 2020, Abstract 5782.